CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 114 enrolled
Drug / intervention
LY2452473 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02499497
NCT02499497Phase 2Completed
CompareCT.gov

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Dana-Farber Cancer Institute·interventional·Posted Jul 16, 2015·Updated Sep 28, 2021

In Brief

A Phase 2 clinical trial evaluating LY2452473 and Placebo for Prostate Cancer. Completed, enrolled 114 participants across 4 sites.

Detailed Summary

This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: \- LY2452473

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Institute of Nursing Research (NINR)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 16, 2015
Enrollment StartFeb 29, 2016
Primary CompletionOct 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 11.0 years ago

Interventions

LY2452473drug

LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.

Placebodrug

The participants will receive pills containing no active drug.